Laser Photonics Corp Q3 FY2026 earnings call

• Strategic Vision: Management is pivoting to focus on four key markets: Defense, Pharmaceutical, Semiconductor, and Industrial. The core strategy leverages quantum mechanics and directed energy technologies, particularly 'Quantum Bullet' laser systems.
• Defense Initiatives: LACE is developing affordable, modular, laser-based counter-drone (CUAS) systems. The first-generation LSAT system will be introduced at ITSEC. The company aims to disrupt traditional defense models by offering cost-effective directed energy solutions compared to kinetic missiles.
• Pharmaceutical Growth: CMS Laser is expanding its CO2 pill drillers into UV-marking anti-counterfeit systems for GLP-1 therapies and personalized medication. Orders are on hand expected to generate revenue next year.
• Semiconductor Expansion: The company has shipped its first molecular-level material splitting system for brittle materials like electronic glass and silicon wafers, moving from prototype to commercial application.
• Industrial Operations: BIMA Laser manufacturing has restarted in Lake Mary with strong bookings. Robotic laser systems for data center equipment manufacturing are being delivered.
• Corporate Governance & Integration: Significant steps taken to improve accountability, transparency, and financial controls. The company name changed to LACE Corp. to operate under three brands: CMS Laser, Laser Photonics, and BIMO Laser. Facilities in Orlando and Maitland have been consolidated.

The transcript does not provide a breakdown of financial performance by specific product segment (e.g., Defense, Pharmaceutical, Semiconductor, Industrial) in terms of absolute revenue or percentage contribution. The company reports consolidated net sales of $1.1 million for the third quarter, up 25% from $0.9 million in the prior year period. For the first nine months of 2026, consolidated net sales were $3.9 million, down from $5.8 million in the same period last year. The decline was attributed to a $1.1 million decrease in laser cleaning products and services and an $0.8 million decline in affiliate net sales.

• Going Concern Warning: Substantial doubt remains about the ability to continue as a going concern for the year following the issuance of Q3 financial statements.
• Q4 Priorities: Focus on establishing a cost structure optimized for current sales levels, improving production capacity utilization, and strengthening internal controls.
• Cash Flow Goal: Near-term objective is to reach operating cash flow breakeven.
• Resource Allocation: Continue serving established pharmaceutical, semiconductor, and industrial markets while allocating increasing resources toward defense opportunities.
• No Specific Financial Guidance: Management did not provide specific numerical revenue or earnings guidance for the fourth quarter or full year 2026.

• Going Concern Status: The company explicitly states that substantial doubt exists regarding its ability to continue as a going concern.
• Financial Performance: Gross margin remains negative at 39% despite an 8 percentage point improvement. Operating cash flow has been negative ($7.4 million used in operations for the first nine months).
• Revenue Decline: First nine-month net sales dropped significantly from $5.8 million to $3.9 million due to declines in laser cleaning and affiliate sales.
• Operational Execution: The defense market is described as 'infancy' with unpredictable revenue. Conversion of order backlog into revenue is uncertain.
• Legacy Disruption Risk: While LACE aims to disrupt conventional defense models, it faces competition from major contractors with significant resources, though LACE lacks the legacy investments that hinder those competitors.

Q: How does the company plan to achieve operating cash flow breakeven given the current negative margins and high operating expenses?

A: CFO Tim Peterman stated that the primary mechanism for reaching breakeven is optimizing the cost structure relative to the current level of sales. This involves improving the utilization of production capacity and implementing more accountable sales processes managed by talented teams. Additionally, the company is strengthening internal controls and external reporting to ensure financial discipline, although gross margins remain significantly negative at 39%. The focus is on stabilizing the base business before scaling new ventures.

Q: What is the strategic rationale behind introducing the 'Quantum Bullet' system at ITSEC, and how does it differ from existing counter-drone solutions?

A: Executive Chairman Dmitry Nikitin explained that the market for counter-drone systems requires affordability, quick deployment, and field repairability, which current systems often lack. The 'Quantum Bullet' LSAT system is designed to be scalable, modular, and capable of operating on various power sources, including batteries. It integrates AI-driven computer vision and precision beam control to offer a cost-effective alternative to expensive kinetic missiles, targeting Group 1 and Group 2 drones specifically.

Q: Can you clarify the revenue status of the semiconductor division and the timeline for commercialization of the molecular splitting technology?

A: The semiconductor business is currently transitioning from the industrial prototype stage to commercial applications. The company has already shipped its first system to customers, utilizing proprietary exclusive license technology for non-dimensional cutting of brittle materials. While this represents a milestone, the division is still in early stages. Management intends to advance these products to generate revenue, but no specific revenue figures or immediate large-scale order timelines were provided for this segment.

Q: Why has the company changed its name to LACE Corp., and how does this support the integration of its acquired brands?

A: The name change to LACE Corp. was part of a broader effort to simplify corporate identity and enhance marketing effectiveness. It allows the company to operate cohesively under three distinct brands: CMS Laser, Laser Photonics, and BIMO Laser. This structural clarity is intended to make it easier for investors, customers, and partners to understand the company’s diverse portfolio and strategic direction, supporting the ongoing integration of recently acquired product lines into a unified organization.

Q: How is the company addressing the substantial doubt regarding its going concern status, and what role do recent equity offerings play?

A: The company raised $19.6 million in net proceeds from equity offerings over the first nine months of 2026, which helped strengthen the balance sheet and repay $6.4 million in notes. Despite having $7.6 million in cash at quarter-end, management acknowledges that substantial doubt remains. The strategy to mitigate this risk involves achieving operating cash flow breakeven through strict cost optimization and converting the growing order book in pharmaceutical and industrial sectors into timely deliveries and revenue.